| ID | 1133 |
| Name of the vaccine | Menjugate |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | Over 2 months |
| Description of the vaccine | Meningococcal group C conjugate vaccine and contains a protein (called CRM197). |
| Name of the manufacturer | GSK Vaccines S.r.l. |
| Name of the manufacturing country | Italy |
| Year of manufacture | 2015 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | 93% effectiveness. |
| Vaccine formulation | Suspension for injection |
| Dosage | For children 12 months and older : Single dose(0.5 mL)
For infants 2 to 12 months: Two doses, at least 2 months apart. |
| Mechanism of action | Induces immunologic memory after vaccination. |
| Route of administration | Intramuscular |
| Indications | Protects against infections caused by Neisseria meningitidis type C. |
| Export | Marketing Authorisation Holder: GSK Vaccines S.r.l., Italy |
| Approval | NA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | NA |
| Side effects of vaccine | All age groups: Redness, swelling, pain at the injection site.
Infants: being sick(vomiting).
Infants and toddlers: irritability, drowsiness, difficulty sleeping, loss of appetite and diarrhoea.
Secondary school children: headache
Older children and adults: muscle and joint pains, feeling generally unwell |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.hpra.ie/docs/default-source/vaccine-pils/menjugate-pil.pdf?sfvrsn=8 |
| Other name | NA |
| Additional Links | NA
|